Back
Results - Announcements
Gland Pharma Ltd consolidated sales up 3.30% on year in Q2FY2026
10-Aug-2026, 06:44
Gland Pharma Ltd share price slipped 0.65% to Rs 2600.45 after the company's net profit contracted by 13.56% to Rs 316.96 crore, while revenue from operations improved marginally 3.30% to Rs 1800.27 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.54 lakh crore, gaining 5.15%. It has inched up 0.74% over last one week and advanced by 13.39% in last one month while the market capitalization of Gland Pharma Ltd has marginally improved by 0.90% and 39.08% in the same period respectively. Profit before tax (PBT) of Gland Pharma Ltd stood at Rs 434.98 crore in Q2 FY26, surging by 39.09% year-on-year, and dropping 14.00% quarter-on-quarter. EBITDA came in at Rs 428 crore, expanding by 38.01% YoY and easing 6.62% sequentially. Total expenses grew marginally by 6.26% to Rs 1422.16 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 588.2 crore, slightly declining by 0.99% YoY, while employee benefits expense was at Rs 444.0 crore, registering a growth of 7.88% YoY. For the TTM ended FY26, revenue from operations advanced 14.50% to Rs 6430.65 crore, while net profit surged by 47.07% to Rs 1027.32 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 110011% to Rs 1313.22 crore, and PBT soared 37.82% to Rs 1464.58 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1031.39 crore in FY26, as against Rs 914.73 crore in FY25. Gland Pharma Ltd jumped 32.87% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.63% during the same period.
Gland Pharma Ltd share price slipped 0.65% to Rs 2600.45 after the company's net profit contracted by 13.56% to Rs 316.96 crore, while revenue from operations improved marginally 3.30% to Rs 1800.27 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.54 lakh crore, gaining 5.15%. It has inched up 0.74% over last one week and advanced by 13.39% in last one month while the market capitalization of Gland Pharma Ltd has marginally improved by 0.90% and 39.08% in the same period respectively. Profit before tax (PBT) of Gland Pharma Ltd stood at Rs 434.98 crore in Q2 FY26, surging by 39.09% year-on-year, and dropping 14.00% quarter-on-quarter. EBITDA came in at Rs 428 crore, expanding by 38.01% YoY and easing 6.62% sequentially. Total expenses grew marginally by 6.26% to Rs 1422.16 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 588.2 crore, slightly declining by 0.99% YoY, while employee benefits expense was at Rs 444.0 crore, registering a growth of 7.88% YoY. For the TTM ended FY26, revenue from operations advanced 14.50% to Rs 6430.65 crore, while net profit surged by 47.07% to Rs 1027.32 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 110011% to Rs 1313.22 crore, and PBT soared 37.82% to Rs 1464.58 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1031.39 crore in FY26, as against Rs 914.73 crore in FY25. Gland Pharma Ltd jumped 32.87% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.63% during the same period.